Pateclizumab
Pateclizumab is a monoclonal antibody that was designed for the treatment of rheumatoid arthritis. It was developed by Genentech, a biotechnology company based in the United States. Pateclizumab targets the interleukin 6 (IL-6) pathway, which plays a crucial role in the inflammatory response that characterizes rheumatoid arthritis.
Mechanism of Action[edit | edit source]
Pateclizumab works by binding to the interleukin 6 receptor (IL-6R), thereby inhibiting the interaction between IL-6 and its receptor. This prevents the activation of the IL-6 pathway, which is known to contribute to the inflammation and joint damage seen in rheumatoid arthritis.
Clinical Trials[edit | edit source]
Pateclizumab has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. The results of these trials showed that pateclizumab was well-tolerated and led to improvements in disease activity scores in patients with rheumatoid arthritis.
See Also[edit | edit source]
References[edit | edit source]
| Pateclizumab Resources | |
|---|---|
|
 |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
